PF-Atlas › Clinical Trials › NCT02140554
A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease
lovo-cel · Phase 1
Registry ID
NCT02140554
Phase
Phase 1
Status
Completed
Drug / intervention
lovo-cel
Sponsor
Genetix Biotherapeutics Inc.
Start
2015-02-02
Enrollment
54
Locations
11
About this trial
This is a non-randomized, open label, multi-site, single dose, Phase 1/2 study in approximately 50 adults and adolescents with severe SCD. The study will evaluate hematopoietic stem cell and progenitor stem cell (collectively referred to as hematopoietic stem and progenitor cells or HSPCs) transplantation using lovo-cel.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02140554 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.